Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
Completed
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 4
2005-06-01
The purpose of this research study is to help in the development of safe, effective and
reversible male contraception. We are examining the impact of the drug Miglustat on sperm
production in normal men.
We want to see if Miglustat will inhibit sperm production in men and act as a reversible male
contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of
sperm production. We believe Miglustat may have some potential as a safe, reversible male
contraceptive.
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
Completed
University of Washington
Phase 4
2005-06-01
The purpose of this research study is to help in the development of safe, effective and
reversible male contraception. We are examining the impact of the drug Miglustat on sperm
production in normal men.
We want to see if Miglustat will inhibit sperm production in men and act as a reversible male
contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of
sperm production. We believe Miglustat may have some potential as a safe, reversible male
contraceptive.
Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease
Completed
Actelion
Phase 3
2006-02-01
Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher
disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are
required to establish the long term efficacy, safety and tolerability of miglustat in
maintaining diseases stability after a switch from ERT.
Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis
Completed
Actelion
Phase 2
2004-07-01
The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat,
OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
